Trial Profile

A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 19 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 May 2026 According to a Tyra Biosciences media release, also present a trials-in-progress poster on SURF302 at the 2026 American Urologic Association (AUA) meeting.
13 May 2026 According to a Tyra Biosciences media release, To date, there are more than 20 patients enrolled at US and international trial sites, and the Company expects to report initial three-month complete response data from both dose cohorts in August 2026.
23 Feb 2026 According to a Tyra Biosciences media release, data from this study will be presented at the 2026 ASCO Genitourinary (GU) Cancers Symposium (ASCO GU). The meeting is being heldFebruary 27, 2026, 11:30 AM to12:45 PM PST, in San Francisco, California.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com